Postmenopausal osteoporosis: Fracture consequences and treatment efficacy vary by skeletal site

Aging Clinical and Experimental Research

Volumn 12, Issue 5, 2000, Pages 330-341

  Epstein, S ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Hip fractures; Postmenopausal osteoporosis; Spinal fractures; Treatment of osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RALOXIFENE; RISEDRONIC ACID;

AGED; BACKACHE; CLINICAL TRIAL; FEMALE; FRACTURE; HEALTH CARE COST; HIP FRACTURE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; META ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; VERTEBRA FRACTURE;

FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; TIME FACTORS;

EID: 0033694898     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03339858     Document Type: Review

References (80)

1. Symptomatic fracture incidence in elderly men and women: The Dubbo Osteoporosis Epidemiology Study (DOES)
2. The crippling consequences of fractures and their impact on quality of life
3. Osteoporosis: Frequency, consequences, and risk factors
4. Prescribing by general practitioners after an osteoporotic fracture
5. Questionnaire survey of advice given to patients with fractures
6. Osteoporosis among estrogen-deficient women - United States, 1988-1994
7. Prophylaxis and treatment of osteoporosis
8. Biomechanics of fractures
9. Epidemiology of osteoporosis
10. Epidemiology of age-related fractures
11. Which fractures are associated with low appendicular bone mass in elderly women?
12. The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: The Geelong Osteoporosis Study
13. Changing incidence and residual lifetime risk of common osteoporosis-related fractures
14. Lifetime risk of hip fractures is underestimated
15. Race and sex differences in hip fracture incidence
16. The incidence of fractures of the proximal femur and the distal radius in Tottori Prefecture, Japan
17. The apparent incidence of hip fracture in Europe: A study of national register sources
18. World-wide projections for hip fracture
19. Guidelines for diagnosis and management of osteoporosis
20. A prospective study on socioeconomic aspects of fracture of the proximal femur
21. The socioeconomic burden of fractures: Today and in the 21st century
22. Quality of life after hemiarthroplasty for femoral neck fracture
23. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women
24. Costs and health effects of osteoporotic fractures
25. The direct medical costs of osteoporosis for American women aged 45 and older
26. Late physical activity and functional effects of osteoporotic fracture in women: The Rancho Bernardo Study
27. Mortality after all major types of osteoporotic fracture in men and women: An observational study
28. Population-based study of survival after osteoporotic fractures
29. Clinical consequences of vertebral fractures
30. The association of radiographically detected vertebral fractures with back pain and function: A prospective study
31. Vertebral fracture and other predictors of physical impairment and health care utilization
32. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures
33. Contribution of vertebral deformities to chronic back pain and disability
34. Personal experience in managing acute compression fractures, their aftermath, and the bone pain syndrome, in osteoporosis
35. Quality of life issues in women with vertebral fractures due to osteoporosis
36. Risk of mortality following clinical fractures
37. Contributions of vertebral fractures to stature loss among elderly Japanese-American women in Hawaii
38. Clinical grading of spinal osteoporosis: Quality of life components and spinal deformity in women with chronic low back pain and women with vertebral osteoporosis
39. The clinical impact of vertebral fractures: Quality of life in women with osteoporosis
40. Hip fractures: A worldwide problem today and tomorrow
41. Epidemiology and consequences of osteoporotic fractures
42. Managing osteoporosis in older people with fractures
43. How hip and whole body bone mineral density predict hip fracture in elderly women. The EPIDOS prospective study
44. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
45. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women
46. Updated data on proximal femur bone mineral levels of US adults
47. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis
48. Prevalent vertebral deformities predict hip fractures and new vertebral deformities, but not wrist fractures
49. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
50. Use of the NOF guidelines with peripheral densitometry to predict fractures
51. Risk assessment for osteoporosis using bone mineral density determination
52. Attitudes to osteoporosis and hormone replacement therapy among elderly women
53. Evidence-based management of patients with osteoporosis
54. Osteoporosis: Trialstribulations
55. Evidence-based medicine and osteoporosis: A comparison of fracture risk reduction data from osteoporosis randomised clinical trials
56. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
57. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
58. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
59. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women
60. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial
61. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
62. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
63. Risedronate reduces hip fractures in patients with low femoral neck bone mineral density
64. Preventing fractures in postmenopausal women with osteoporosis: A review of recent controlled trials of antiresorptive agents
65. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial
66. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
67. Prevention of nonvertebral fractures by alendronate: A meta-analysis
68. Prevalent vertebral fractures predict hospi talization and mortality in older women: The Fracture Intervention Trial (FIT)
69. Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis
70. Vitamin D supplementation and fracture incidence in elderly persons
71. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
72. Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women
73. How long should patients with osteoporosis be treated with bisphosphonates?
74. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group
75. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib
76. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates
77. True strength